Nasdaq previously suspended the trading of 23andMe’s Class A common stock, $0.0001 par value per share (the “Common Stock”), at the opening of business on March 31, 2025 and notified the ...

23andMe's market cap peaked at $5.8 billion ... and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in 1993 in Alexandria, VA., by brothers David and Tom ...

On May 19, Regeneron Pharmaceuticals (NASDAQ: REGN) announced that it was the successful bidder for substantially all of 23andMe's assets, agreeing to pay $256 million for them. The deal is still ...

Me (OTC:MEHCQ) faces a second auction after a $305M bid challenges Regeneron's (REGN) initial bid for its assets. Read more ...

Human genetics testing firm 23andMe announced Tuesday it will voluntarily delist from the Nasdaq and deregister with the U.S.

Regeneron Pharmaceuticals REGN has emerged as the successful bidder in the bankruptcy auction for most of the assets of 23andMe Holding Co., a prominent player in human genetics and biotechnology.

(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN), an American biotechnology company, on Monday announced that it planned to acquire 23andMe Holding ... at $596.39 on Nasdaq.

PITTSBURGH, May 22, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI ... Pharmaceuticals announced its acquisition of 23andMe for $256 million, marking a strategic step in the ...

Regeneron Pharmaceuticals said earlier this month that it will acquire “substantially all” of 23andMe’s assets for $256 ...

Genetic testing company 23andMe is preparing for a renewed auction of its assets after a federal judge agreed to reopen the ...

This initiative follows Regeneron Pharmaceuticals' acquisition of 23andMe, which underscores ... Predictive Oncology Inc. (NASDAQ: POAI) moves to leverage its vast biobank of more than 150,000 ...

SAN FRANCISCO, May 27, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (“23andMe” or the “Company”) (OTC: MEHCQ), a leading ...